IP Library Patent Application 11430745
Patent Application
App. No. 11/430,745

Enhancing the circulating half-life of antibody-based fusion proteins

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/430,745
Abstract

Disclosed are methods for the genetic construction and expression of antibody-based fusion proteins with enhanced circulating half-lives. The fusion proteins of the present invention lack the ability to bind to immunoglobulin Fc receptors, either as a consequence of the antibody isotype used for fusion protein construction, or through directed mutagenesis of antibody isotypes that normally bind Fc receptors. The fusion proteins of the present invention may also contain a functional domain capable of binding an immunoglobulin protection receptor.

Claims (10)

1 . A region of a gene construct encoding an antibody-based fusion protein, the region including:

at its 5′ end, nucleotides encoding at least a portion of

1) an IgG1 CH2 domain with a mutation or a deletion at one or more amino acid residues corresponding to amino acid positions set forth in SEQ ID NO:1 selected from the group consisting of Leu234 and Leu235, or

2) an IgG CH2 domain with a mutation or a deletion at one or more amino acid residues corresponding to an N-linked glycosylation site,

said mutation or deletion reducing binding affinity for an Fc receptor (FcR), and wherein said portion comprises a domain required for immunoglobulin protection receptor (FcRp) binding affinity, and

at its 3′ end, nucleotides encoding a non-Ig protein.

2 . The region of claim 1 , wherein said non-Ig protein is a cytokine.

3 . The region of claim 2 , wherein said cytokine is an interleukin.

4 . The region of claim 1 , wherein the region is fused at its 5′ end to nucleotides encoding an immunoglobulin hinge region.

5 . The region of claim 1 , wherein the region includes nucleotides encoding, in a 5′ to 3′ orientation, the at least a portion of an IgG CH2 domain and at least a portion of a CH3 domain.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2008
From: EMD SERONO RESEARCH CENTER, INC.
To: MERCK PATENT GMBH
Reel/Frame 021138/0674 →
CHANGE OF NAME Recorded May 20, 2008
From: EMD LEXIGEN RESEARCH CENTER CORP.
To: EMD SERONO RESEARCH CENTER, INC.
Reel/Frame 020963/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2006
From: GILLIES, STEPHEN D.; LO, KIN-MING; LAN, YAN; WESOLOWSKI, JOHN
To: EMD LEXIGEN RESEARCH CENTER CORP.
Reel/Frame 018193/0412 →